Full Text View
Tabular View
No Study Results Posted
Related Studies
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
This study has been completed.
Study NCT00208312   Information provided by CV Therapeutics
First Received: September 13, 2005   Last Updated: October 1, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Coronary Artery Disease
Additional conditions recognized in this trial
Coronary Disease
More general conditions related to this trial
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Interventions listed in this trial
Regadenoson
Adenosine
More general drug interventions related to this trial
Analgesics
Anti-Arrhythmia Agents
Cardiovascular Agents
Central Nervous System Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
CV Therapeutics
Astellas Pharma US, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services